Drug Development Process and Clinical Research
What this domain tests
This domain tests your command of the development cascade from discovery to post-approval, the vocabulary of trial design and biostatistics, and GCP obligations. Questions often ask you to read a result and state what can and cannot be claimed.
Core rules
- Preclinical GLP toxicology and pharmacology support the IND (US) or CTA (EU) before first-in-human dosing; Phase 0 microdosing studies are exploratory.
- Phase I: safety, tolerability, PK/PD, maximum tolerated dose, typically 20–80 subjects, often healthy volunteers (oncology patients for cytotoxic agents).
- Phase II: signal of efficacy plus dose-ranging, roughly 100–300 subjects. Phase III: pivotal, confirmatory, label-enabling. Phase IV: post-authorisation commitments, safety surveillance, real-world evidence.
- Design elements: randomisation, allocation concealment, blinding, placebo or active control, pre-specified primary endpoint, sample size and power calculation, interim analyses with alpha control, DSMB oversight.
- ICH E6 GCP, IRB/IEC approval, informed consent, protocol deviation handling, ITT versus per-protocol analysis.
Worked example
A Phase II study reports progression-free survival HR 0.78 (95% CI 0.62–0.98) as the primary endpoint, and overall survival with p = 0.04 as a secondary endpoint. Reasoning: the primary endpoint met its pre-specified significance, but the trial was not powered for OS and no alpha was allocated to that secondary endpoint. The OS finding is hypothesis-generating and cannot be described as demonstrated survival benefit in a label claim or promotional context.
Traps that cost marks
- Calling a Phase II signal "proven efficacy".
- Confusing statistical significance with clinical relevance or with regulatory approval.
- Treating an uncontrolled secondary endpoint p-value as confirmatory.